文献速递甲状腺疾病

显性甲状腺功能障碍与抗甲状腺抗体可预测癌症患者对抗PD-1免疫治疗的应答

Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
PubMed 文献 · Thyroid · 2020-04-23

研究纳入168例接受纳武利尤单抗或帕博利珠单抗治疗的非小细胞肺癌、肾细胞癌和转移性黑色素瘤患者,每周期前检测促甲状腺激素和游离T4,基线和治疗2个月检测抗甲状腺抗体。治疗期间出现显性甲状腺功能障碍者总生存和无进展生存均优于无甲状腺功能障碍者,抗甲状腺抗体水平高于中位数者生存也更优。

要点

  • 治疗期间出现显性甲状腺功能障碍者1年总生存率94% vs 59%,无进展生存率64% vs 34%。
  • 治疗期间抗甲状腺抗体高于中位数者1年总生存率83% vs 49%,无进展生存率54% vs 20%。
  • 基线抗甲状腺抗体水平对无进展生存和总生存具有临床相关性。

核心结论

  • 抗PD-1治疗期间获得性显性甲状腺毒性与高于中位数的抗甲状腺抗体水平与改善的无进展生存和总生存相关。
  • 基线抗甲状腺抗体水平对无进展生存和总生存具有临床相关性。

研究设计与样本

  • 纳入168例接受纳武利尤单抗或帕博利珠单抗治疗的非小细胞肺癌、肾细胞癌和转移性黑色素瘤患者。
  • 每次抗PD-1输注前测量促甲状腺激素和游离T4水平。
  • 基线和治疗2个月时测量抗甲状腺抗体(抗甲状腺过氧化物酶和抗甲状腺球蛋白)水平。
  • 抗甲状腺抗体截断值预先设定为研究人群基线浓度的中位数。
  • 肿瘤进展按RECIST v1.1分类。

主要发现

  • 治疗期间出现显性甲状腺功能障碍者较无甲状腺功能障碍者总生存显著更高(HR=0.18,95%CI 0.04-0.76,p=0.020),1年总生存率94% vs 59%。
  • 治疗期间出现显性甲状腺功能障碍者较无甲状腺功能障碍者无进展生存显著更高(HR=0.39,95%CI 0.15-0.998,p=0.050),1年无进展生存率64% vs 34%。
  • 治疗期间抗甲状腺抗体水平高于中位数者较低于中位数者总生存更高(HR=0.39,95%CI 0.21-0.72,p=0.003),1年总生存率83% vs 49%。
  • 治疗期间抗甲状腺抗体水平高于中位数者较低于中位数者无进展生存更高(HR=0.52,95%CI 0.33-0.81,p=0.004),1年无进展生存率54% vs 20%。
  • 持续抗甲状腺抗体水平高于中位数者较持续低于中位数者总生存更高(HR=0.41,95%CI 0.19-0.89,p=0.025)且无进展生存更高(HR=0.54,95%CI 0.31-0.95,p=0.032)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Thyroid dysfunction is among the most common adverse effects during anti-programmed cell death 1 (PD-1) immunotherapy, and alongside correlations with elevated anti-thyroid antibodies (ATAb), studies have found correlations with survival. However, the exact relations remain to be clarified. We, therefore, aimed at clarifying the relationship between thyroid dysfunction, ATAbs, and survival in anti-PD-1 treated cancer patients. Methods: We included 168 patients with nonsmall-cell lung carcinoma, renal cell carcinoma, and metastatic melanoma treated with nivolumab or pembrolizumab. Thyrotropin and free T4 (fT4) levels were measured before each anti-PD-1 infusion. ATAb levels (anti-thyroid peroxidase [TPO] and anti-thyroglobulin [Tg]) were measured at baseline and after two months of treatment. Although the vast majority of patients had detectable levels of ATABs, only a few patients had positive ATAbs when using conventional cut-offs. To study the consequences of detectable ATABs, the cut-off levels were a priori set at the median concentrations at baseline in the study population. Tumor progression was classified according to RECIST v1.1. Results: Patients who acquired overt thyroid dysfunction during treatment had significantly higher overall survival (OS) (hazard ratio [HR] = 0.18 confidence interval [CI: 0.04-0.76]; p = 0.020) and progression-free survival (PFS) (HR = 0.39 [0.15-0.998]; p = 0.050) than patients without thyroid dysfunction with 1-year OS rates of 94% vs. 59% and 1-year PFS rates of 64% vs. 34%. During treatment, patients with ATAb levels above the median had a higher OS (HR = 0.39 [0.21-0.72]; p = 0.003) and PFS (HR = 0.52 [0.33-0.81]; p = 0.004) than patients with ATAb levels below the median, with 1-year OS rates of 83% vs. 49% and PFS rates of 54% vs. 20%, respectively. When analyzing ATAb levels over time, patients with a persistent ATAb level above the median had a higher OS (HR = 0.41 [0.19-0.89], p = 0.025) and PFS (HR = 0.54 [0.31-0.95], p = 0.032) compared with patients with a persistent ATAb level below the median. Patients whose ATAb levels increased above the median during treatment had an improved OS (HR = 0.27 [0.06-1.22], p = 0.088) and PFS (HR = 0.24 [0.07-0.77], p = 0.017) compared with patients whose ATAb levels decreased below the median. Conclusions: Acquired overt thyroid toxicity and above median ATAb levels during anti-PD-1 treatment are associated with improved PFS and OS. In addition, our results suggest that ATAb levels at baseline are of clinical relevance for PFS and OS.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Basak EA, van der Meer JWM, Hurkmans DP, et al. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. Thyroid. 2020. PMID: 32151195. doi:10.1089/thy.2019.0726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。